New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
10:21 EDTMDWDMediWound IPO indicated to open $15.50
MediWound (MDWD) priced 5M shares at $14.00. Credit Suisse, Jefferies and BMO Capital acted as joint book running managers for the offering.
News For MDWD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
16:59 EDTMDWDMediWound says second EscharEx Phase 2 clinical trial meets primary endpoint
MediWound announces positive top-line results from the company's second Phase 2 clinical trial evaluating EscharEx for debridement of dead or damaged tissue in chronic and other hard-to-heal wounds. EscharEx is based on the same propriety proteolytic enzyme technology used in MediWound's NexoBrid, which is approved and commercially available in Europe and Israel for the removal of eschar in adults with deep partial- and full-thickness thermal burns. Effective debridement is a critical first step to facilitate wound management and is complementary to existing wound healing products, which require a clean wound bed. This trial was the second Phase 2 trial with EscharEx, following a feasibility Phase 2 trial, conducted in Israel with 24 patients that demonstrated the ability of EscharEx to debride chronic and hard-to-heal wounds of various etiologies. The objectives of this second Phase 2 trial were to evaluate the efficacy of EscharEx in debriding chronic wounds, to assess its safety and lack of deleterious effect on wound healing and to further analyze these effects in different etiologies to guide the design of future pivotal studies. The study met its primary endpoint with statistical significance. Patients treated with EscharEx demonstrated a higher incidence of complete debridement compared with patients treated with the hydrogel vehicle. The study included secondary endpoints that provide further insight on a number of efficacy and safety parameters. The secondary endpoint of time to complete debridement demonstrated a clear trend that strongly suggests that not only is there a difference in the incidence of debridement, as confirmed by the primary endpoint, but that debridement occurred earlier in the group treated by EscharEx.
January 25, 2016
16:38 EDTMDWDMediWound files $125M mixed securities shelf
16:38 EDTMDWDMediWound files to sell 11.64M ordinary shares for holders
Subscribe for More Information
07:03 EDTMDWDMediWound reports Q4 EPS (36c), consensus (23c)
Reports Q4 revenue $267,000, consensus $230,000.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use